Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05248750

Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma

Status
Recruiting
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Pancreatic ductal adenocarcinoma (PDAC) complexity, where genetic, stromal, and immunological factors all interact with each other, is responsible for the overall poor response of PDAC to chemotherapeutic agents, making this a lethal disease. The investigators hypothesize that: (i) dissection of genetic, stromal, and immunological factors on endoscopic ultrasound fine needle biopsy (EUS-FNB) tissue samples from unresectable PDAC patients' will allow to determine prognostic factors in this patient population; (ii) treatment response and acquisition of tumor chemotherapy resistance could be related to genetic heterogeneity between the primary and metastatic sites and alteration of the molecular profile under drug' selection pressure.

Conditions

Timeline

Start date
2021-07-22
Primary completion
2024-07-10
Completion
2026-07-10
First posted
2022-02-21
Last updated
2024-02-13

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05248750. Inclusion in this directory is not an endorsement.

Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma (NCT05248750) · Clinical Trials Directory